NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC cut its holdings in NewAmsterdam Pharma (NASDAQ:NAMS) by 8.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,715 shares of the company’s stock after selling 3,450 shares during the quarter. Lisanti Capital Growth LLC’s holdings in NewAmsterdam Pharma were worth $995,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC lifted its stake in NewAmsterdam Pharma by 35.6% during the third quarter. FMR LLC now owns 330,412 shares of the company’s stock valued at $5,485,000 after purchasing an additional 86,712 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of NewAmsterdam Pharma by 1,231.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock valued at $3,972,000 after acquiring an additional 221,305 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of NewAmsterdam Pharma by 176.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock worth $371,000 after acquiring an additional 14,280 shares in the last quarter. State Street Corp grew its holdings in shares of NewAmsterdam Pharma by 168.7% in the 3rd quarter. State Street Corp now owns 37,915 shares of the company’s stock worth $629,000 after acquiring an additional 23,805 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of NewAmsterdam Pharma by 1.6% during the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after purchasing an additional 1,399 shares during the period. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Trading Up 2.1 %

NewAmsterdam Pharma stock opened at $23.50 on Friday. NewAmsterdam Pharma has a 1-year low of $15.19 and a 1-year high of $27.29. The firm’s fifty day simple moving average is $22.24 and its 200-day simple moving average is $20.43. The company has a market capitalization of $2.17 billion, a P/E ratio of -9.04 and a beta of -0.06.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $3.30 million. On average, equities research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

NAMS has been the subject of a number of recent analyst reports. Scotiabank increased their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Thursday, February 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Needham & Company LLC cut their price target on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $43.80.

Insider Transactions at NewAmsterdam Pharma

In other news, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80. Following the sale, the insider now owns 10,908,502 shares in the company, valued at approximately $284,711,902.20. This trade represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James N. Topper bought 4,005 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the purchase, the director now owns 3,012,434 shares in the company, valued at approximately $63,321,362.68. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 554,927 shares of company stock worth $13,446,287. Company insiders own 19.50% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.